Producción CyT
Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension
Artículo
Autoría:
Ghelfi, A.M. ; Miranda, G. ; Voto, L.S. ; Del Sueldo, M.A. ; Zilberman, J.M. ; Mondino, R. ; Pérez, M.P. ; Irusta, P.G. ; Meccia, L. ; Martínez Marissi, E. ; Laura Baiche, M. ; Waisman, F. ; BaronI, M. ; Victoria FerrettI, M. ; Morán, J.P. ; Corrales Barboza, A. ; Delucchi, A.M. ; Rodríguez, P.D. ; RENNA, NICOLAS FEDERICOFecha:
2024Editorial y Lugar de Edición:
El sevierRevista:
Hipertensión y Riesgo Vascular - ISSN 1889-1837El sevier
ISSN:
1889-1837Resumen *
Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria. The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine. The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence. Información suministrada por el agente en SIGEVAPalabras Clave
EmbarazoAmlodipinaAntihipertensivosAdherencia